Advertisement

Picture Swiss Biotech Association LSA Global Village 2025 Basel 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Asia or involving organisations from these countries.

Total search results: 1530 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Mitsubishi Chemical–Bain Capital: investment, 202502– carve-out acquisition JPY510b ($3.3b) of Mitsubishi Tanabe Pharma Corp by Bain Capital 2025-02-07
Bureau Veritas–SGS: investment, 202501– confirmed merger discussion 2025-01-15
Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures 2025-01-15
Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital 2025-01-15
Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital 2025-01-15
Bioptimus–Hitachi: investment, 202501 financing round totalling $41m incl co-investor Hitachi Ventures 2025-01-14
Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation 2025-01-14
Umoja Biopharma–SEVERAL: investment, 202501 financing round Series C $100m co-led by Double Point Ventures + DCVC Bio 2025-01-14
Daiichi Sankyo–Glycotope: antibody-drug conjugates, 202501 acquisition all IPRs $132.5m for use of gatipotuzumab in ADC DS-3939 2025-01-13
Normunity–SEVERAL: investment, 202501 financing round Series B $75m co-led by Samsara BioCapital + Enavate Sciences 2025-01-13
Windward Bio–Kelun Pharmaceutical: TSLP antibody, 202501– license ww excl China + smaller Asian markets to WIN378 from Kelun-Biotech + Harbour Biomed 2025-01-10
Windward Bio–Nan Fung: investment, 202501 financing round Series A totalling $200m incl co-investor Pivotal bioVenture Partners 2025-01-10
Windward Bio–Qiming: investment, 202501 financing round Series A totalling $200m incl co-investor Qiming Venture Partners 2025-01-10
Windward Bio–Quan Capital: investment, 202501 financing round Series A totalling $200m incl co-investor Quan Capital 2025-01-10
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities 2025-01-10
Roche–Innovent Biologics: antibody-drug conjugate, 202501– collab + excl ww license to IBI3009 with $80m upfront + $1b milestones plus royalties 2025-01-02
Astellas–Sangamo: drug delivery for gene therapies, 202412– license excl ww $20m upfront + up to $1.3b use STAC-BBB capsid 2024-12-19
Innovent Biologics–Lilly: pirtobrutinib, 202412– distribution excl commercialisation of Jaypirca in mainland China by Innovent Biologics 2024-12-16
Syncell–SEVERAL: investment, 202412 financing round Series A $15m led by Taiwania Capital Bio Fund bringing total raised to $30m 2024-12-11
Syncell–Taiwania Capital: investment, 202412 financing round Series A totalling $15m incl lead investor Taiwania Capital Bio Fund 2024-12-11
Biotheus–BioNTech: investment, 202411– acquisition 100% for $800m upfront mostly in cash + few ADSs plus $150m milestones 2024-11-13
Centogene–Charme Capital Partners: investment, 202411– acquisition €8.7m of sole operating subsidiary Centogene GmbH by affiliate of Charme Capital 2024-11-13
Alentis Therapeutics–Morningside: investment, 202411 financing round Series D totalling $181.4m incl existing + co-investor Morningside VI 2024-11-12
Alentis Therapeutics–SEVERAL: investment, 202411 financing round Series D $181.4m led by OrbiMed with co-leads Novo Holdings + Jeito Capital 2024-11-12
Nuclera–E Ink: investment, 202410 financing round Series C totalling $75m incl existing + co-investor E Ink Holdings 2024-10-16
Nuclera–GK Goh: investment, 202410 financing round Series C totalling $75m incl existing + co-investor GK Goh 2024-10-16
Nuclera–PERSON: investment, 202410 financing round Series C totalling $75m incl co-investor Michael D McCreary 2024-10-16
Nuclera–SEVERAL: investment, 202410 financing round Series C $75m led by Elevage Medical Technologies (Patient Square Capital) 2024-10-16
Innovent Biologics–Aosaikang Pharmaceuticals: limertinib, 202410– distribution excl commercialisation of limertinib in mainland China by Innovent 2024-10-08
Yumab–Molcure: AI-based drug discovery, 202410– collab expansion to incl zero-shot AI Ab discovery technology to discover Abs for undrugged targets 2024-10-08
Kurma–SEVERAL: investment, 202410 first closing of Kurma Biofund IV with target for final closing of €250m 2024-10-03
Roche–Regor: CDK inhibitors, 202409– acquisition $850m cash upfront + milestones of portfolio of CDK inhibitors by Genentech from Regor 2024-09-30
Resonac–Altaris: investment, 202409– acquisition 100% of Minaris Regenerative Medicine Subsidiaries of Resonac by Altaris LLC 2024-09-26
Shan Foods–Symrise: foods, 202409 strategic collab existent Pakistan + UAE + KSA incl joint production plant in Pakistan 2024-09-20
Cell Signaling Technology–e-Blot Life Science: imaging system, 202409– distribution of Touch Imager system by Bioké in 12 European countries 2024-09-16
Abolis Biotechnologies–Clay Capital: investment, 202409 financing round totalling €35m incl investor Clay Capital 2024-09-12
Abolis Biotechnologies–SEVERAL: investment, 202409 financing round €35m with BOLD L’Oréal VC Fund + Evonik Venture Capital et al 2024-09-12
Organon–Bao Pharmaceutical: long-acting FSH, 202409– license + supply agreem for SJ02 in Mainland China $12m upfront + milestones 2024-09-12
PhoreMost–SEVERAL: investment, 202409 financing round Series B extension $12m bringing total round to $50m led by Parkwalk Advisors 2024-09-10
Candid Therapeutics–SEVERAL: investment, 202409 launches with $370m investment raised via multi-step financing 2024-09-09
eGenesis–SEVERAL: investment, 202409 financing round Series D $191m from existing + new investors led by Lux Capital 2024-09-04
Vignette Bio–EpimAb Biotherapeutics: bispecific antibody, 202409– license ww outside China $60m upfront cash+equity + $575m milestones + royalties 2024-09-04
Vignette Bio–EpimAb Biotherapeutics: investment, 202409 equity investment as part of $60m upfront payment in cash + equity in license deal 2024-09-04
Vignette Bio–Foresite Capital: investment, <202409 seed financing round incl lead investor Foresite Capital 2024-09-04
Vignette Bio–Mirae Asset: investment, <202409 seed financing round incl co-investor Mirae Asset Capital Life Science 2024-09-04
Vignette Bio–Qiming: investment, <202409 seed financing round incl co-investor Qiming Venture Parnters USA 2024-09-04
Vignette Bio–Samsara BioCapital: investment, <202409 seed financing round incl co-investor Samsara BioCapital 2024-09-04
Vignette Bio–SEVERAL: investment, <202409 seed financing round led by Foresite Capital 2024-09-04
Vandria–Hevolution Foundation: investment, 202408 financing round Series A 2nd closing totalling CHF10.3m incl new investor Hevolution Foundation 2024-08-21
Vandria–SEVERAL: investment, 202408 financing round Series A 2nd closing CHF10.3m bringing total Series A to CHF28.3m 2024-08-21
PL BioScience–LePure Biotech: investment, 202408 financing round Series A totalling €7.8m incl new investor LePure Biotech 2024-08-08
PL BioScience–SEVERAL: investment, 202408 financing round Series A €7.8m with new + existing investors 2024-08-08
NEC–Asahi Glass: contract manufacturing, 202408– collab developm production techn + supply cancer vaccine NECVAX-NEO1 by AGC Biologics + NEC Bio Tx 2024-08-07
Leon-Nanodrugs–SEVERAL: investment, 202408 financing round Series D led by new investor LBBW Venture Capital 2024-08-06
Kirin–Biomatter Designs: enzyme design, 202408 collab existent development of enzymes for production of Human Milk Oligsaccharides (HMOs) 2024-08-05
AIRNA–SEVERAL: investment, 202407 financing round Series A extension $60m led by Forbion brings total Series A to $90m 2024-07-31
iotaSciences–SEVERAL: investment, 202407 equity financing round from existing + new investors for business expansion 2024-07-31
Ono Pharmaceutical–Systasy Bioscience: drug target discovery, 202407– collab research fees + milestones to identify + validate targets in neurology 2024-07-31
Synthetica Pioneering–Boehringer: investment, 202407 financing round Series A incl co-lead investor Boehringer Ingelheim Venture Fund 2024-07-30
Synthetica Pioneering–SEVERAL: investment, 202407 financing round Series A led by Boehringer Ingelheim Venture Fund + Temasek 2024-07-30
Revir Therapeutics–5Y Capital: investment, 202407 financing round Series A totalling $30m incl existing + co-investor 5Y Capital 2024-07-26
Revir Therapeutics–CDH Investments: investment, 202407 financing round Series A totalling $30m incl existing + co-investor CDH Investments 2024-07-26
Revir Therapeutics–CMT Research Foundation: investment, 202407 financing round Series A totalling $30m incl new + co-investor CMTRF 2024-07-26
Revir Therapeutics–Lapam Capital: investment, 202407 financing round Series A totalling $30m incl lead investor Lapam Capital 2024-07-26
Revir Therapeutics–SEVERAL: investment, 202407 financing round Series A $30m led by Lapam Capital bringing total raise to $54m 2024-07-26
Revir Therapeutics–XtalPi: AI-based drug discovery, 202407 collab existent 2024-07-26
Revir Therapeutics–XtalPi: investment, 202407 financing round Series A totalling $30m incl new + co-investor XtalPi 2024-07-26
Revir Therapeutics–Yael Capital: investment, 202407 financing round Series A totalling $30m incl existing + co-investor Yael Capital 2024-07-26
BioNTech–Triastek: 3D drug printing, 202407– collab developm + license $10m upfront + $1.2b milestones plus royalties 3D printed oral RNA drugs 2024-07-23
CytoReason–Nvidia: investment, 202407 financing round totalling $80m incl investor Nvidia 2024-07-17
CytoReason–OurCrowd: investment, 202407 financing round totalling $80m incl investor OurCrowd 2024-07-17
CytoReason–Pfizer: investment, 202407 financing round totalling $80m incl investor Pfizer 2024-07-17
CytoReason–SEVERAL: investment, 202407 financing round $80m from OurCrowd + Nvidia + Pfizer + Thermo Fisher 2024-07-17
CytoReason–Thermo Fisher: investment, 202407 financing round totalling $80m incl investor Thermo Fisher Scientific 2024-07-17
Draupnir Bio–Mitsubishi Chemical: Investment, 202407 seed financing round totalling €12m incl new investor MP Healthcare 2024-07-17
Draupnir Bio–SEVERAL: Investment, 202407 seed financing round €12m with MP Healthcare + EIFO + Gilde HP + Inkef Capital + Novo Holdings 2024-07-17
SK Group–Full-Life Technologies: radionuclide-drug conjugate, 202407– license ww excl up to $571.5m to FL-091 anti-NTSR1 to SK Biopharmaceuticals 2024-07-17
Catalym–Brandon Capital: investment, 202407 financing round Series D totalling $150m incl existing + co-investor Brandon Capital 2024-07-16
Catalym–Canaan Partners: investment, 202407 financing round Series D totalling $150m incl new + co-lead investor Canaan Partners 2024-07-16
Catalym–SEVERAL: investment, 202407 financing round Series D $150m led by Canaan Partners + Bioqube Ventures 2024-07-16
Huma Therapeutics–Hitachi: investment, 202407 financing round Series D totalling >$80m incl investor HV Fund 2024-07-16
Huma Therapeutics–SEVERAL: investment, 202407 financing round Series D >$80m (alongside investments from industry partners since Series C) 2024-07-16
Scorpion Therapeutics–SEVERAL: investment, 202407 financing round Series C $150m led by Frazier Life Sciences + Lightspeed Venture Partners 2024-07-16
Element Biosciences–Fidelity: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Fidelity 2024-07-11
Element Biosciences–Foresite Capital: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Foresite Capital 2024-07-11
Element Biosciences–Rockefeller: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor Venrock 2024-07-11
Element Biosciences–Samsung: investment, 202407 financing round Series D totalling >$277m incl co-investor Samsung Electronics 2024-07-11
Element Biosciences–SEVERAL: investment, 202407 financing round Series D over $277m led by Wellington Management 2024-07-11
Element Biosciences–T Rowe Price: investment, 202407 financing round Series D totalling >$277m incl existing + co-investor T Rowe Price Associates 2024-07-11
Ipsen–Foreseen Biotechnology: antibody-drug conjugate, 202407– license ww excl to FS001 up to $1.03b 2024-07-11
Endoron Medical–SEVERAL: investment, 202407 financing round Series A $10m led by Sofinnova Partners 2024-07-09
Myricx Pharma–Brandon Capital: investment, 202407 financing round Seires A totalling £90m incl existing + co-investor Brandon Capital 2024-07-08
Myricx Pharma–SEVERAL: investment, 202407 financing round Seires A £90m led by Novo Holidngs + Abingworth 2024-07-08
Nucleai MD–Proscia: AI-based diagnostics, 202406– collab integration of Nucleai predictive biomarker solutions into Concentriq s/w platform 2024-06-25
Iambic Therapeutics–SEVERAL: investment, 202406 financing round Series B extension $50m led by Mubadala Capital + Exor Ventures 2024-06-18
Adcytherix–Pontifax: investment, 202406 seed financing round totalling €30m incl lead investor Pontifax Venture Capital 2024-06-11
ITM–Qatar (govt): investment, 202406 financing round totalling €188m incl exisitng + co-investor Qatar Investment Authority 2024-06-06
ITM–SEVERAL: investment, 202406 financing round €188m led by Temasek + including other exisitng investors 2024-06-06
ITM–Temasek: investment, 202406 financing round totalling €188m incl exisitng + lead investor Temasek 2024-06-06
Brandon Capital–Hesta (AU): investment, 202406 first closing of Brandon Capital Fund VI totalling AUD270m incl existing investor Hesta 2024-06-04
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Stier Group MIXiii 2025 Lifescience Healthtech Conference 650x300px

» top